SYNH - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Syneos Health Third Quarter 2019 Earnings Conference Call. At this time all participants are in a listen only mode. Later we will conduct the question-and-answer session and instructions will be given at that time.

I would like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

Ronnie Speight

everyone. morning, Good our the Executive on Michelle are Macdonald, Paul Alistair our Solutions. With Jason call Meggs, Chief Colvin, and Solutions; Officer; of Officer; of our our Clinical President me Commercial today President Chief Keefe, Financial

statements release, the results company our our of These expectations, filings. materially to on under slide presentation at plans, ended purposes about and from obligation are our risk future investor.syneoshealth.com. the factors the Remarks XXXX, of of statements for growth, update In prepared press corresponding forward-looking differ by and Litigation other Safe is financial indicated remarks prospects results the SEC addition for result Harbor constitute these Private discussed forward-looking a Form the year in to make may disclaim the Reform and section anticipated XX-K available those website to for of Act we factor that December as we factors. provisions them. our XXXX, important any XX, a Actual various Securities

be operations. financial non-GAAP in we consider for, accordance be non-GAAP events core discuss of certain and exclude prepared a considered to and which to, not this call, a our effects During transactions the should will we measures supplement measures measures, outside of These replacement with GAAP.

our most GAAP measures, comparable presentation. directly please reconciliation a the the financial the of appendix to with For of measures non-GAAP refer

turn the to over like Alistair? now would Alistair I call to Macdonald.

Alistair Macdonald

you and Thanks, Ronnie. Good morning, for joining today. thank us everyone,

profitability. to in remain healthy across discuss did, We the encouraged in with which be experienced model short-term across trajectory Clinical in our growth, by RFP continue confident to however, and Jason We pipelines segments. flow revenue commercial strong market very engagement headwinds for long-term Solutions. encounter Clinical quarter, We our growth Solutions customer in our detail. integrated more will some and our continued third Commercial growth we overall build the segment and for During strong momentum and

Importantly, in our Syneos One unique and offering grow. product market development evolve interest continues to

performance a with start highlights. few me Let key

adjusted currency in third our Solutions of Clinical of in driven was currency of growth X.X% X.X% or or and X.X% the was XXXX. to by Commercial constant in This constant First, growth X.X% quarter constant total Solutions or revenue X.X% currency. X.X% growth compared

solid XX-month a Second, and X.XXx we performance billion awards in and with of This an $X.X of of which maintained a address will the shortly. aggregate X.XXx quarter, ratio clinical book-to-bill sales than book-to-bill overall higher for trailing more of despite cancellations detail of commercial comprised period, book-to-bill this I was normal net X.Xx.

very we Third, regarding insights. lab to we receiving, has This to in model been the model, companies access our life deep large pharma feedback enthusiastic development pharma product particularly fueled are by product about instrumental differentiated expanding from been and large our development comprehensive positive capabilities have customers.

partner us customers' align Syneos preferred One validating clinical our company, pharma market the of our our leverage existing clinical and approach out This the trial provider optimize capabilities to to transactional will One-driven of methodology optimize this preferred delivery relationship highlighted to excited product delivery from to the award the QX with am company. our of assets. unique first relationship of our of most power a the long-term I win large a with is relationship, series to to a announce evidence a of on impact, commercial As one how and partner. important moving our pharma deep insights large goals. utilizing call. Syneos provider win portfolio and relationship customers' our commercial strategic marks This addition we This a in recent understanding market, This proprietary an with another development grew a clinical

business. by Solutions results quarter. Clinical awards Now strong turning the gross experienced our third in to

and X customers. due the believe This X.XXx. of expected. of issues up safety X.Xx would To awards XX-month their idea ratio resulted with XX-month our higher-than-normal total in have isolated were trailing $X.X X.XXx lower these period clinical an cancellations, the last these CNS cancellations, for give cancellations excluding due efficacy the been to net for than book-to-bill compounds of of were book-to-bill trailing We you ratio from magnitude, However, events to quarter. billion, period, awards net producing a

to at to solid X.X%, expect up which Our growth forward. provider year-over-year growth backlog continue new our ramp and also we remained we fuel relationships, moving

communities, have enable placed Sites. with through Society Eagle including us were enduring sites we global on to with model that highlight Validating Award build patients deep honored consecutive the I'm Research that very our the recently serve. program, site our proud strong the catalyst Our third for and relationships they Clinical to insights delivers we emphasis from relationships

professionalism, Award employees engaging CRO Eagle belief of thank engaged the of trial is successful clinical behalf demonstrating shortening in real clinical through is strong This execution dedication that the not the on research site the patients our distance life. every the collaborate vision converting finding partnerships. want advance world leadership, a achieve I from who approach award but recognizes to databases, also the a The to integrity, to management and to them of them to passion our and of trial our research key in and participants. reflection exemplifies site clinical patients partners lab that outstanding just day site-focused clinical core to trial to all into profession best accelerate

commercial decisions partners to through to design capabilities behavioral allows insights We about make better, our us more that site using a help new listening people ways to patient believe confident leverage health. engaging them social community our communications and their as catalyst

by awards for delays impacted a also book-to-bill pressure Our customer Commercial awards quarter, to of in net third awards during certain experienced we net of in trailing decisions. typical XXXX, segment Solutions delivered period XX-month or Xx. the billion and the were Similar $X.X seasonal

expect a XXXX. in continued growth which have of to fuel to continue we However, strong we opportunities, pipeline

the evolve MSLs as commercial the leader we and engage value and our in nurse space, educators forward-looking in such with continue to channels conversations As omnichannel and solutions. customers discussing market access,

capabilities Our broad on to performance engagement patients our a and improved better and behalf beyond groups, of that communities payers size drives outcomes. physicians, reach and building group stakeholder advocacy of commercial customers

also novel to lines. and see our time We accelerate One customers product development development continued strong solutions interest all provides in with which to commercialization unique offering, sizes Syneos of outsourcing

I Learning pharma specifically to into companies Syneos development customers from indications won discussions. early evidenced expertise other limited This model success is the Syneos relationship evolving One for smaller earlier. We've turnkey the midsized internal by large biopharma solutions, our also bandwidth. companies, implement provider have from One new highlighted awards preferred where pharma is with or may

continues and In to affords to addition, these optimize unique management a with provider. alternative pipeline Syneos a opportunities customers the outsourcing One single-source, portfolio grow of efficient

by the product who to XX,XXX-plus employees Syneos expressing better, close to again performance. advance my Health like to once appreciation smarter, identify and continue ways development speed faster to I'd clinical

all every patients Our improve efforts across of lives our help worldwide. the sectors, day customers

performance. turn comments to me let Now financial it more over Jason? Jason on for our

Jason Meggs

you, and Thank good everyone. Alistair, morning,

defined or discussed on results on reminder, X. non-GAAP as basis adjusted all a are Slide an As

ASC the period adjusted comparisons XXX We current results reimbursable an will expenses. discussing basis, on period-to-period which includes be and

detail. results reviewing our begin in financial me by Let

XXXX up Slide in when $X.XX third foreign revenue to quarter quarter $X.X X.X% shown currency of up of As exchange X, excluding constant the and adjusted our for third compared the headwind million. of on X.X% billion, a XXXX was

last slower over Our year-over-year driven the grew currency reimbursable $XXX by Clinical expenses or a X.X% of revenue constant awards was million in revenue on growth growth segment net basis. by and and mix, favorable adjusted XX impact FX. offset revenue to the a X.X% partially Clinical months

X.X% Commercial the our other Commercial largely attributable slower a driven revenue coupled the than up growth anticipated, delay Commercial was offset to an preceding adjusted adherence decline to which year-over-year months delays higher in business, partially $XXX.X in large in medication currency. in a Our constant reimbursable revenue net segment awards impact was mix customer by nonrenewals. and primarily revenue X.X% FX. unfavorable to project and consulting, in XX deployment and and million due and by expenses, growth was up program the revenue of solutions was with growth over

would commercial of single growth medication quarter the XXXX. digits compared to isolated our third been Importantly, revenue adherence, excluding headwind high the in organic have

EBITDA consistent with benefits X.X% an adjusted million adjusted EBITDA of When includes the we've the EBITDA basis for was X.X% of XXXX quarter quarter the by exchange for the margin guidance. our EBITDA XX.X%. highlighted, of Adjusted EBITDA Adjusted million, year-over-year for $X impact points. quarter is third a increased $XXX.X contemplated benefit million, increase previously the in of for $X.X resulting third of third in grew margin foreign XX and adjusted normalized timing our

favorable the clinical of growth, by growth offset benefits operating realized in were large new adjusted EBITDA driven mix, in of performance customer our $XX These was before of reinvestments startup strategic to and unfavorable the overall synergies increase revenue costs improved synergies approximately third by the million The the during impact growth. commercial associated with leverage. revenue realization partially drive previously discussed. the the Adjusted relationships of EBITDA and revenue quarter includes net

adjusted Adjusted diluted our tax EPS of lower primarily EBITDA driven rate. XX% non-GAAP our growth and by year-over-year, $X.XX in grew by

diluted Specifically, of to quarter tax during rate the EPS improved our growth adjusted contributed third $X.XX XXXX. the

turning sheet on Slide X. flow as balance summarized to cash and the Now

third flow million as-reported operations XXXX, of quarter in Cash primarily accounts declined to utilization the an the $XX.X During third from lower quarter, provided of our arrangement. to factoring operations receivable cash our compared on due basis.

of ended was unrestricted the debt outstanding cash $XXX.X XX.X million $X.XX and We quarter the for billion. total days. of with DSO quarter

as deployment debt capital shareholder Slide while balanced repayment, as focused as on repurchases capital market well deployment by investments our management opportunities share acquisition, conditions X determined and activities. provides available This optimizing capital an structure. drive also to on includes tuck-in debt our and update flow We approach value. and to cash a remain

repaid $XX.X B with and we maturity of and flow. capacity receivable quarter, million During third represents lowest an increased the million which refinanced facility our of of being free cost securitization from We accounts Loan our accounts $XXX.X million the cash our coming our facility, the with receivable $XX debt. Term additional extended securitization

were the of senior also also of capacity free premium. stock redemption $XXX.X $XXX the used to $X year. we flow, our feature the available stock, October, through Term along loan and In which, We to proceeds our of draw with common cash our of million the of redeem notes beginning be fund delayed A. end X.X% executed repurchase outstanding million The repurchased leaving the on million utilized

leverage in of saving. was expense will Although transaction this interest we result future estimate annual neutral, it $XX million

rate XX of tax points. XX%, third quarter a rate year basis adjustment the reflecting revised of full non-GAAP our Our to was our for the effective of expectation XX.X%, decrease

$XX to benefit internal given our million the pleased year controls. cash outlay NOL million also taxes we the remediation weaknesses that net remain deductions, communicated, full actual for I'm report be disclosed material previously on the to to our our of As of in XXXX. teams expect focused for previously $XX

We final have process. ongoing of internal completed process, our and although testing certification our as control largely part remediation evaluation audit and annual is

in as no favorable with resolution. work the thorough investigation to and its our want achieve August, internal for action. enforcement advisers Lastly, thank SEC we has team, quick their our concluded announced Board I to our recommended a

now Turning Slide guidance X. our to on

also a revenue to commercial reminder, strength adjusted expenses. strength the clinical to our the to between guidance are adjusted last revenue third headwinds updated the revenue fourth we quarter, but quarter further As clinical this mentioned. due and guidance reflect to adjusted our and segment, slightly timing our incorporate largely We're I previously in guidance reducing increased of the revenue due reflect quarter reimbursable increasing to

to adjusted or our of As increasing adjusted to billion to range dollars to reducing clinical X.X% are Accordingly, Alistair of revenue these X.X%. growth short-term full includes noted, This nature. representing billion our $X.XX $X.XX $X.XX range billion a to are billion, XXXX growth we expected year X.X%. for headwinds revenue to in we believe X.X% $X.XX

or While $X.XX $X.XX adjusted reducing a X.X%. to of to our revenue growth to billion commercial range billion X%

with now due $XXX million the expected remaining to higher range expectations from million total Our unchanged, $XXX adjusted for primarily synergies. midpoint to EBITDA

million rates; adjusted for existing our and assumptions: synergies This EPS estimated based and following are approximately and merger $X.XX key of guidance to prior foreign current increasing $X.XX. million; shares, rate on and to interest cancellations delays; the We share third share count of reinvestments; in revised pipeline, including to any XXX.X $XXX effective $XXX range interest quarter. diluted our expected rates, exchange our million tax of our to is resulting expense currency million trends sales to non-GAAP backlog subsequent XX%; estimated excludes $XXX the repurchases approximately expected which of

be will we and questions. any remarks, answer prepared happy our completes to This Operator?

Operator

line the from comes comment or Sandy question of first Draper Our instructions] [Operator SunTrust. from

Sandy Draper

you guess, service first, a sense if your the lower? flip don't see it around, us how guys net look in may I it can pass-through higher give the been I the revenue, But have or much have you move I to of book-to-bill. you trying just would book-to-bill under talk. know impacted know at really revenue can any I'm

Alistair Macdonald

Sandy, that just we of start question. lost you Can right please? at repeat the that, you

Sandy Draper

Sure.

Sorry, can now? you hear me

Alistair Macdonald

Yes.

Sandy Draper

Okay.

just you But book-to-bill you focus in moving don't really XXX directionally impact right book-to-bill having quarter? know I on know whether didn't was in just about revenue you or I I say of anymore, up Can impact and of -- understand. know a revenue Sorry. down. I on in pass-through can pass-through quarter-to-quarter fluctuate or terms -- now positive could if the terms which talk negative

Alistair Macdonald

take Jason that -- to want you Do one. will

Jason Meggs

little that the of the pass-throughs a it think give we've -- fact overall. bump I about did talked bit Sandy, historically

something I like our book-to-bill. think was that, it X.X like to or

We haven't that have different seen didn't time, then proportion we cancels basis. particularly that And have sort is we larger did about the chain of any prepared programs underlying you materially that of anything talked really as in a in the over the remarks, that X at either. look from really TTM when there

Sandy Draper

get commentary maybe, partnership guess new you My case, My you is that Syneos new congrats the bit it's -- then relationship. you is versus Are just about Alistair, really deal. in just are think in more won And business? a differentiated guys little there. that you the this execution, X when what to on Syneos, -- basic preferred who do think people there One on understanding

Alistair Macdonald

Sandy.

So won the in just partnership to partnership morning provider preferred the this in one we've QX. for clarify, -- to discussed -- preferred addition we we is

-- feedback won I'll that we QX couple they in for similar a of but collectively win address won that of So ways. others. public actually couple another both display -- that reasons. a displaced are alongside CRO, The the because we a we've one in of subtly is different, couple the And is

development. kind fact stand-alone team, deliver to commercial large to over as stand-alone ability bridge services, we of -- Our sectors ability to work clinical from the clinical to commercial customer side. great commercial Michelle's a enabled insights the that clinical They bring the and the the that was us originally or have like into

commercial, with clinical we see brings that of seeing came One the seeing what starting we're we're and that. we here are we is, always, that. What Syneos So rationale from actually, larger now, we is bring and out that and also merger commercial the would feed the to a certainly that getting larger is the around pharma the and really insights to to customers. reimbursed, market now it alignment we getting appealing those product have the commercial in actually

asset supersized really morning, So is an with level, relationship. the we've announced on new customer. that this it's development one around, effectively this really a It's a just One product relationship Syneos

II, asset have, this the relationship I, at based So Phase the the is rather level. win than III, go Phase new fight and to Phase and the having we

with the the clinical gets to asset, wherever fails write develop it protocols, all way them et World Evidence, goes to in it all to through, it Real bring the So through we're or way cetera, whether to, to the working through commercialization. it

We'll with engaged way asset. along with customer the be all that this

what of the just kind approved, that's the drug, are. it's more getting in the had of power, insights, Syneos a the not whole current a the that but whole patient long with, And the relationship getting I a it model. Syneos They're way. that very clinical we've It's alignment goals approach, design and customer ultimate differentiation, a around So capability, think their that different that's a commercial actually the transactional and One

to to getting and One that align with model is get a point them where they're customer reimbursed.

model. it table. So now the and we the pulling in insights patients we're to line sites, cetera, scale over on use the seeing differentiator how the the side it's But have and horsepower gets the the understanding at and the I that all enroll that clinical, we on et in us get think the that to them that's commercial and

Operator

Erin comes from or next Suisse. the line comment from Our Credit question of Wright

Erin Wright

evolving on the I One I guess was the benefit I in well? clinical $XXX there. that end-to-end that wanted end-to-end assisted guess correct where I we that you've if does awards. check progress that does from that Syneos where And the of last it wins, I'm Syneos I Syneos guess think customers? as had in an in another some you provided. it's to additional And One. And quarter, business those stand about million. overall $XXX also you now? guess think million on into metrics wins was and said how recently representing One X about stand should from then project more I

Alistair Macdonald

and morning, for thanks Good questions. the Erin,

of the number customers and answer have. I'll opportunities So we

we Syneos XX in now have So customers One.

X. the which the XX think at So where And was that that we of looking middle that's year. it up it. the Jefferies numbers well And around update I at. normally from we're were in is we do We we uptick year. think substantial from a a twice as other the I I the that assets think one in do JPM, model,

see numbers at customers of So working we're the and of we'll in assets that can that. update from number that But can a you on, kind substantial see expect point. to lift you the

Erin Wright

you guess potentially hiring have about business some And All I ahead should X announced. now Okay. of thinking right. And be large the that building you've how to then partnerships we patterns here?

Alistair Macdonald

are separations important projects thinking able is they're them good out little or to come to therapeutic separate can therapeutic work. And when question. And of Yes, there's off, resourcing. a team It's, on group a obviously, the when indications when news degree, we down, projects some bit step finished over on to indication big come about have, we're good out, a like they clinical that's new with we a when those move the overlap. you're

So it some like of will that. get built

always do model, model. staff with we XX% who partnerships the try in and XX%, in Syneos Syneos are One with seed is right, of them What large the health kind to seasoned or

then to So pretty you're we're resourcing do is we this where are does et because how systems, go? know project at side, is to? of people et be where the going they're then and cetera. that And cetera, The need What MSLs, et CRAs, we at to add clinical always looking cetera, that pattern the of protocol-specific because it looking take the key-off the on who to focused. And therapeutically geographically resources sites processes, that. kind

think I is see bookings. of those programs. relationships we'll We're front pull-through of to in in of because already build projects, in QX, QX headwind one XXXX in front of starting some margin those the those seeing

to continue start that X, So see of staff we're we we beyond. of of obviously ahead that we that starting just need to, get through, XXXX to expect from curve the that. how the out those work see once protocols, and And then and awards one we

a in I smiling But sure Paul's So getting it's do up think we're at recruitment job to and make able good absorb work we time. good me. be stood to the of side. that going those a to lot in of built be now

Operator

David comment or comes Jefferies. the Our line from next Windley question from of

David Windley

your remarks in Alistair, around momentum. this That the, prepared bookings. understand, and your that release as frustratingly into partnerships, the these not talking about building translating I description certainly supports is qualitative about you're press discussion

all fairly have there's your In in look in third have the XX deck, that down or specifically, a third XX that. the Slide if a cancellation book-to-bills kind we You've ticked highlighted your of quarter year. month impact cancellations certainly on trailing couple sizable that an quarter of in

there or or flow from affecting have so us where partnerships? may progress? some book-to-bill RFPs you the are And onboarding bookings win in of help to understand in where been production of these Or would in delays if of spot market your rates

Alistair Macdonald

good Yes. Thanks, Dave, morning.

we collectively have saying company since history, pipeline the we over very the X has some is relationship. at getting out business the have partnerships because in highest they've I see pipes to and the after think in partnerships that from will ever both been significant sectors XX seen had that really, of slow start won last The initial months strong. start the So right? has reprioritization I we them moment by we've that So that stages getting that it RFP these we were of focus merger up, the awarded one had,

on we're always from think we've and I had expected the one second QX, to in a a and one we I QX, see The with. those we call that customer start is relationship that. to new bookings the that And starting last said think

to that expect ramp We up.

and pull-through yes, assume, cancellation as anybody I So outsized not very compounds, I a from CNS everybody, that I'm more at efficacy right than for now. but mean on is would X not interim seeing as that a I means, substantial, out well, any The frustrated X canceled and we're a trend canceled bookings in report mean that, to QX and X analysis by DSMB.

of. So monitoring the didn't some look safety like that safety signals on they board,

taken customer's program the So down. the

them Yes, We tracking the weeks of an but of take literally of immediately out have they on each the the little elevated for of back we towards It's to we've and within There's they're those and just the end other kind sometimes, finish no quarter, both risk backlog. a thing. right treatment, of out. we're each of kind We out people projects, cancellation, on we take X of cancel down, them kind top of titrate de-risk starting bit. other of backlog. luck standard as people of care, out And those that of off off them to bring us. in been

if don't mean focused the are it in start individual X.XXx, the trailing X at them and I bookings. We're than take We you winning piece. we the we been policy So been is assets the on impact XX. can't would months, of We're rather take very doesn't make direction. sales we right into within X.XXx bookings they in back projects, have our would which were because saw We wanted have impactful. to sure overall guys that. heading

forward chronologically, be of go we're as quarters. kind as bookings we So to subsequent take those into into we'll able enter we

$XX think I where see. to momentum, So happy we've very And many with that into them translating you that when not times CNS years like about in we very book-to-bill X profile. a heading a We're means bookings. project runs before when talked with book-to-bill project about we're X we're and million years, million what guys really just a $XX in talk different get clinical oncology takes you

very we're heading. yes, through I it wish pull was them policies where we're bookings Paul, happy our into any? translating doesn't allow So, cancellations. actually, and that a we and monster but apply book-to-bill, way the the to

Paul Colvin

Yes. hit I again, I point. mean, think key the you've on

got I both these discussion. a instances, pipeline going on. and complete with transparency timing we've is think what's In partnerships their on this

I these the as decision and points moving that but have we that partnerships. think ramped know is we've been we've had coming. forward short-term see what seen the been delayed, in we assets There some that are

partnerships we're about talking we're in timing a experience, again, issue into at us good have that these ramp. really And X what's visibility coming. think my I discussing, these least really So given

think is point in It's as So they the future. I the we do coming that ramp up. think a on partnerships timing that

David Windley

provide to of commercial. longer, this applies could making I I mean, same the think risk the you question At

from trending down You that it's said been a X.Xx and -- book-to-bill, all away long. away of year kind and

Alistair Macdonald

Yes.

we've some of made, the less we that we seasonal see when were to year at of we out with this but hope changes think seen effect it. X.XXx came Commercial's I last of seasonal, kind year, I think. we

commercial So QX, see we're be And QX, expect we trend back quarters, to establishing for go like, if come you and in QX. that the are then going that down bookings. QX that will for up to us down,

much us us CRO in of not help number is on in we that that up and up. So be it with in going the going businesses, see more front a like smooth line, I see I budget clinical, And to BD we're think are quarters the cycle as drive will straight But I the we going out it's to any? can suppose, side try industry, than end, as see, to Obviously, Michelle you commercial, lot powering to next is and seemingly. seasonality. across etcetera. to mean, by distinct you're back the work couple that commercial for the of commercial going a this

Michelle Keefe

nice David, to your hear voice.

So little decisions have delayed QX, have you've more to We heard have me the those QX before, timing and and provide a think customers traditionally We've here, that right? versus do bought clarity. I'll right. And some just right. longer pushed to had are some the on we issues. they decisions, I things make we decisions say did buying -- They they integrated more longer maybe that of solutions, take tactical types they're past, and take in --

decisions. into news the that still So exciting those visibility we is have on The that. had some are So table, push in good right? that's good some for us we have

consulting's it MSLs marketing. at really reimbursement capabilities with evolved-types just We've pipeline And the specialists is omnichannel an into not because high. and and model but evolved our importance as our shared, the integrated as well Alistair extremely remains right. We've opportunities, of talked talked offerings. mean all-time about the of of I importance sales these communications almost nurses representatives, integrating and it's high. as exciting they're Secondly, about

So interest level very the very, high. remains

development is I the think business. through cycle, mature the life those Syneos some other exciting commercial that the customers opportunities move clinical huge One that as are thing has product for and really now right got assets nice

bullish being business. So we're obviously, very at what our business. to the opportunity to the to make sure that And continue convert to mid-single-digits. That's I before, for is as I based But book-to-bill is we there towards the on job, said David. grow business, North able convert that we But X.Xx Star. need We're my see, always that. convert commercial to on working

we're about that. So excited

Operator

comment from from Eric next of Baird. line Our or question the comes Coldwell

Eric Coldwell

I X. actually have

know CNS cancels shorter on they're I term studies. XXXX? quantify the revenue First impact off, you could in

Yes. So I about much if risk-weighted thinking there? to how some of what us just had you advance, need didn't know that in we be could signal give you

Jason Meggs

Eric, it's Jason.

given at going And and planning larger least of Alistair X So as they're that midflight, obviously, some to to the transition studies having over. said, that. It's now take at X starting in time. we're of the season is look to

look awards. backlog a impact had see that not to the relative the and year we study impact we typically might the the what think, when you book-to-bill So on it's And long -- very slotted, CNS also, as longer-term just given at program. next is as the on one then the significant

Alistair Macdonald

Yes.

study always. through -- of patients' is at I that softens and closing So clinical, the titrating the to it. bit biggest And then I of that. patients that I of one we're reallocated in also that that one awards cancellation patients ever ones take et to we've QX to Even a resistant kind next now. they'll QX, add the is those Eric, I cancellation, But probably will But we're safety, it the be probably things going that think off of which we've year. size sites the in think the our think We is scale the and had QX, sure some making kind which power seen. and time backlog -- is, people of on think, of to out can through cetera, takes

Eric Coldwell

I outlook our building you for cautious headwind, there. deals. when be engagements? as But on also a margin building stating XXXX we margin then X little maybe you with you And next overall these for one, talk signaling big new my you're more obvious ramp start the to the to partnerships, the are need the, about know the

Jason Meggs

our that relationship what customer, the this been margin about build business again. we in year. mean, headwind the the you with that margin in drop partnership going out. see out say the revenue year, ramp have Jason we Eric. tailwind. start performance in on can the XXXX, building this Based and have to as discussions build on has What a Yes, there, of others slot say we out. front is to those It's I us then been and that would to we've a there the talking been I to give That is all you the

about think that's it. that's coming about the thinking So Plan's mentioned, I way that we're how as would I it. but together, still

Eric Coldwell

And the clearly, be year come I these I'm to my one, over or directional you X mean need thoughts the these kind as stuff you pockets growth commercial on next update willing then of last But air But through a of asking on rework some there. know numbers down here. forward-looking in and revenue give I to Okay. rates would lot delays?

Alistair Macdonald

Yes.

me I'll start, and to let So you pass Jason, Eric. over

year is think as us where commercial in a Michelle growth part Like This QX. into speed we the commercial. clinical is pipeline well. I build really, of we're starting backlog, drive said, clinical, help seeing what to that is QX, the the record from which

So And when bullish allocated sector. budgets very we're and get in assigned it. the that on

we So what make we like We line it a can't see clinical. like straight there.

see. that advantage seeing we kind But And wanted an which end-to-end, development pull to clinical that. the actually what want We've is the to it. we're now product that, of customers, overall from whatever seeing always giving us you the known on it we're with something call is through. And us larger brings over differentiation to side it's

great and I we're for on commercial. pattern the very think Jason? growth bullish for still that's us,

Jason Meggs

tried how not piece is are a here. backlog timing we Alistair quarter we're about, adherence the that X.X. it quarters drive added right, drive the And the it's, But given to we're at thinking to that our looking see it about, When Eric, at to temporary giving on what best and back Wall medication Based place. we're believe is where a and on quarter XXXX to up Yes. and has reasonable the outline guidance growth. is, us what X see we talked in Street those I pipe and on, and near what Michelle record. X as mean, we we seasonality

Operator

comes question Peterson of comment Tycho or Morgan. next JP from line the from Our

Tycho Peterson

follow to couple ask. the up want A to I on preferred deal. provider questions of

Just, seems new narrower you little That bit partnership. being one strategic to typical on talked than the a asset about tied deal. a

the the impact So talk margins. EBITDA extend that in opportunity maybe on or other add can partnership? then assets also you therapeutic area about to And the

of on impact sort how You but the we curious touched question, just to can margin? Eric's develop it

Alistair Macdonald

the for to you the multiple take first then probably Yes, pass I'll Tycho. over assets, the and Well, second Yes. one relationship. it's Jason one,

to discussions believe on get-go. transactional that and asset the class assets from couple news we we're asset that, manner. one good across working from And a this in multiple the will them, asset. additional more, in there, expand. it's an the with We're of an adding starts So working already on a the these, They're of assets not

it's quarters, get So not of we It's benefit you should, which as them should assets, that. couple isolated about, to across we next to bring on over multiple the And hopefully of one product. we're very the obviously. look excited

commercial, consulting, now and And that way as something starts this Michelle relationship clinical all pulls cetera. Evidence, phase, World the through across actually, Real through et through said, is late in

it's So piece fashion. full Syneos much a kind the in more One supersized of

that. about excited very we're So

Jason Meggs

first won, the had been And they partnerships. question, starting mentioned changed that point margin growth I prioritization some we And, XX to Yes. and talking earlier nothing building XXXX and the from should our start relieve Tycho, one given to this pressure about being others that, increase and to we've going Eric's what these on, I we're basis given behind as have perspective, their XXXX, XX the targeting projections, mentioned to that delays, has after earlier, but ramp and that from to in is internal probably it. ramp going

Tycho Peterson

then And through? commercial, you that way flagged on you And the of project its about provide you little working How delays. then in term, can think color some Alistair, headwinds do other you here near a adherence? Okay. medication more cited the the on

behind that? what's curious Just

Alistair Macdonald

Yes. Sure. Tycho. Sure,

QX durance the big, assignments of medications On is contracts a delay couple that expect well, QX really, just adherence the when and a is those gets always come to medication in side, renewals. we all on. its kind of

through that I of for at overall, provide that So interest we're that lot we'll see solution a commercial, we XXXX in looks. more comes kind integrated organizations and the there. level in how seeing And commercial as think, that a within higher

in ago, selling move a to team away we that we're to growth a years platform, Not just of couple the kind seeing and seen of backlog talked starts the a get that MSLs We've clinical and I start continuously. work consulting projects, we commercial into projects, just that as in second It's, diversifying field commercial, starts small guess about to to field selling as projects, mature out the mid-customers where to stickier up from Syneos we beyond. from from of picking great convert much more sorry, half much integrated, of branding communications that's commercial. some XXXX where One through over into

bring back book-to-bill quarters as we've to sales of big ahead that up well. got So, and these us

Michelle Keefe

would without is I that for would single growth think headwinds, medication high I earlier that the thing only The in Sorry. digits add adherence the organic said we be commercial.

offering. So the underlying the I think of it shows strength

Jason Meggs

and mentioned... Yes, we

Alistair Macdonald

ahead, Go Tycho.

Tycho Peterson

going just ask to was DSOs. I on

on year. now XX, headed? were at you touch last you those think the you XX Can in You're at are where just

Jason Meggs

these I the our that in we to customers. prepared remarks, that partnerships we, we look I Yes, side the to mentioned at working the then going pressure on continue mean, target just use of to factoring of too. facility did probably some going that's we're leverage have that's with something And pharma pressure, our through. doing, given less one coming into we're will And some large cause cause new And it. that on

from reasonable XXs high place, to And think where sort flattish where are. and quarter we to a is three. mid saying two been we're we of that's is we've So quarter

at. So that's looking we're what

Operator

from Jones Our Sachs. of comes Goldman question from line comment to next Robert the

Robert Jones

of medical XQ sounds sounds kind feel solutions, be Great. back consulting, XQ. out, deployment commercial delays, on like guess to big bookings a quarter lot And, you like obviously, should these just that I revenue like the the adherence, you the guys the It of declines follow or of for in side. some pointed in commercial. Alistair, it whether the it up come the as been think has on you

sense being or to of environment on? play Any you anything there's commercial customers that or it tactical, broader fears shortfalls out price you these Or pushing behind around do more saw this really think talking you pricing what these drug business the Is is of have of anything going of things delaying any in the something some of that? kind quarter? more a to for around thought like just in there

Alistair Macdonald

more what's daily doesn't be environment, know underneath be, these are it two them, Bob, I on anything discussions It drug with headwinds pricing tactical with to U.K., my of so be or But it seems from when The happening, kind seem symptomatic mean come up I'm tactical. customers who to The much. political one term. seems that. to right, basis. a short doesn't out U.S.,

a certainly level and getting absolutely we're short-term, terms I level interest the stand-alone encouraging. we at in of seeing of discussions those, level a penetration higher look The that as getting, commercial clinical seeing RFP of the is it's we're the we're believe the and think inclusion we're are with into in we cetera, the as well et One of partnerships, commercial very encouraging. very as Syneos delivery

I that? mean, anything your you underneath have seen Michelle, in discussion,

Michelle Keefe

Yes.

right? mean I are that leaders to pharma a see, is strategic their They past in the imperative, into senior flexibility really in more models. So I've one many many as I this I of said things outsourcing the think companies want and looking build to

around so how that, do do right? having conversations And you we're

how asking. to So they're that model? you a -- getting into that I'm bigger sense strategic not figure there's out that build do How question any your is there

issue a tactical the absolutely at is timing it and think issue a I time.

Robert Jones

adjusting just going being far go doing as you as for put anything going of think out projects you back is But they you're some caused just I policy quarter months. as years, just the know of at that's time then play it, risk guys off you amount cancellations even to to good feel are in to to a produce have No, do is differently CRO, a and and X it's programs? few revenue anything and if a cancellation, there I detail. of have if partners Or guess a this have this not And three cancellations. some price molecules of the to of But to to X and I a like maybe think based know in? last years assessing the if you I looking think Alistair, the helpful. couple be guys last of is, volatility not years, covered in kind changed, X from big catch or the time clinical over guidance of again, I

Alistair Macdonald

or clinical and in. white take there's don't think backlog We So our very in the put really way a policy out think cancel. black things awarded I just we risk clean. they it. when is they I And to policy. and hit our things think when take things on complexity that. it's it's We I as adjustment I mean, our they're

cancellation INC winning brought I at higher really the the -- I the organizations huge. the think, like. take, that that at together, this that and mean history risk effect, it's the customers we of think really class remember our work, was a complicated of right? I couple on one had talked you wrong that's those complex big when products, the of that had the drug in, complex the when we binary identified we you XXXX, of we've of I win they risk tracking And -- an of elevated of certainly can And the if that end and that pain because that of CNS our binary about of look that cancellation these they of -- they class chance history therefore big actually Like in. a X were end they're been been cancel. programs are -- of they we've while, first-in-class, we're a them for those. the customers

for we've we think don't won it's it's I business a been So think a historically. the have. we the while. just I tracking policy of But them nature that

I larger know, mean, that sector because baked to your experience the think a the getting harder, the a bit of from get shot into of I risky, goal risk now they're little I III, that less -- is -- for on as a think it's I are, a cancellation less of there's big some the Paul, products don't that? optimistic little a Phase predictable bit When they lower we're of less of they're stage more you the large there. pharma. bit pharma in

Paul Colvin

organization. longer longer I No, the it's drug is material be It's research. issue over changing our size related not a of scale, our to entire timing I going And fundamentally quarter think to cancellations is of X, don't a part a it's period at look it not I makes if period something across just really issue mean time. over that -- time, and a but

Alistair Macdonald

from weren't effective were -- really mean because canceled, class they have I perspective, some any treatment. these just states disease but wish of right, these don't for new assets also not our of we Yes. that

bad but So and around, all advancing from these just not are of care. cancellations us treatment terms patient financially, in also

Bob, that's all So didn't that yes, we cancel, can wish did. they I but say, they

Operator

Kreger or next of the Our Blair. William line question John comment from from comes

John Kreger

laid side. out preferred big you've the so across clinical cancellations wins, some Alistair, Great. impressive pretty partnership some but also

you when currently? feel year in or you're about growth So seeing slower 'XX what that than like those think takes, and does a bit a puts better business maybe little

Alistair Macdonald

very we to we'll been before and right? But the got high, look new engine at regular through XXXX, us. fact rate, even position when So therapeutic that when RFP great though. bullish products through, won be at at on factors that we've we that, We've that about. quarter's these got got the got we're merger, got window, wouldn't how -- have, coming partnerships And at clinical of these things would you flow, look out integration. the this We've competing partnerships, new finishing that unusually very in, positives that's visit, very XXXX. in large we optimistic look we -- got are, yet integration start John. rate flow I we a things see that work we So we I for starting have that the months pipes when pull X think cancellation into never them. we when dates work, new cancellation the in We've a look coming we feel patient, I as that then of We've certainly, coming online. within around three you They're all we coming to at We've the starting the bookings, pull I the sitting lot just them look running. And see the invite And over be specialists at before Jason? We've first behind them got to think the have in. first online. X where got what right? when the pull to least should through

Jason Meggs

mean, stand and cancellations when that John, up said X% to the Yes. these that year quarter. at this that X.X%, from getting as I exit in But or we've some year, ramp us you anticipate the as And Obviously, we partnerships. that our we given there. a we've sort of look growth see growth relationships to and being the don't impact. move material as would these continuing impact we have mentioned, the to scale size do

still So at we've up, said past. looking we're in as moving that the

John Kreger

a pricing get some then X up about margins? benefits, relationships do ramp, there you, impact think be, that how there's Are as to follow And some Very too. large you those would would how scale I going assume helpful. you're but also probably preferred

So just that climb? impacts you to your drive as those think about curious how X ability improvements margin

Jason Meggs

will some to there as of we we this in there, we've margin XX these that some headwind I and mentioned the I rapidly start we've articulated. partnership partnership, new getting will throughout a you relief headwind build anything the standing XX is up. That is had and everything days the point year. to 'XX. to like the these growth looking moving when year, have target mean, Yes. don't start just that prevent going see this partnerships as us forward new That up, like basis in more it's little it the certainly infrastructure from with early XXXX partnerships first give out bit that into us from but that from partnership, But that

Operator

Evercore or the next Anderson ISI. from Elizabeth comes line of Our comment question from

Elizabeth Anderson

Just or levels you changes just broadly Is there taking RFP the of in terms like funding anything in can in broadly? industry. generalized back you more step a to point

Alistair Macdonald

the I Elizabeth, kind in the little customers trended biotech at lot is ones I index of But think down that years market been, think the of funding the a the cash funding think levels I are, has a good. dip has customers, X.X, certainly have out dealt when our the going And I've that lot hand. over X a with that of and years, bit.

buffer lot in that. there's So a of

been have flows RFP think I normal.

of We we've seen some uplift you with larger I more these some see customers. kind that longer getting of on, a an that. think think these out because we're partnerships insight into I of of coming get RFP

at that see is when mean, market, pretty all up. still I strong. right feel lift you the I SMID So look that on RFP thoughts Paul, flow I But any that?

Paul Colvin

If amount in mean I coming RFP market, flow SMID at look in clinical, No, to still the we're it's for speaking highest I the double-digit been. ever level flow it's the clinical, of through. seeing growth RFP at the

Alistair Macdonald

Yes.

Paul Colvin

years. more up to SMID the mentioned. starting significantly but prior growth, by, the not we've from being from that's partnerships driven be It's seeing And growth just

see to And going XXXX. are flow we into So that see that's we'll strongly that some upside. as I as into well QX where feel

Elizabeth Anderson

I contribution of do the quarter, the of the a elaborate is probably kind is it's of on sort a realize And of in more question. But this terms there partial but anything can there? to housekeeping of you contribution quarter,

Paul Colvin

last the change year. mean, year, to close last I was year-over-year, August immaterial was that relative an given

Operator

UBS. the Our next Dan comment question from or Brennan line from of comes

Dan Brennan

a quick Maybe the lay. first, adherence on one medication

to does that contract, So quarter? come your going the is after in that that of Or that fourth expected the is come quarter to new with fourth imply kind it's guidance?

Jason Meggs

Yes, Dan.

customer as mentioned not of the and happened. we that we move felt going year, had we supply-demand a like was through the last improve had half that quarter challenge So a we that to demand, back that has

do us spend as that not see yet our is for on products. they've we has in that also of a that decisions challenge the that made not half, a guidance. some we still anticipate we causing their just worked fourth And an have had is sponsor at that's one relative expected point got of look also at budget in quarter. the that we that's not coming through do that and And of was of second that through, some thing, not the contemplated way and headwind. those its more to then supplier, we So through but nonrenewals issue then retailers And the coming some

So come those will aren't guidance. not and in contemplated through the

that is we so terms What that So to we're being see, turning we've we that up that's though, see year, at flattening when nature. in this you back starting for XXXX, had right? in the decline to of that looking short-term and shape pipeline next XXXX out, do look in where around

Dan Brennan

ramping? Like maybe how as just rate, think then should just light And on out of beyond, wondering particularly partnerships quarter that? the about fourth burn we and in we the look new

Jason Meggs

Yes, quarter is it a rate, midpoint the things stronger of if look little through. flat. been bit to guidance X, fourth quarter the historical our flat. basically And you a pushes a of is get at burn little rate, implied everyone burn Well, given then pushed that's

things that we're, what nature. orders and of that's contracts changing So and

So that's what we have right now.

Paul, that. if know talking we're we that, it lengthens at little it comment, But, and as because this the bit. up a stand that are comment a could and as year, don't on next but Paul to you taking be plan finish we to can want Looking these look partnerships I about

Paul Colvin

positive the until I bit to come we're of of that us and the development could And the the across elongate asset No, But period. a into start an start-up into value enrollment on in think protocols sight engagement, partnerships get I think from which much will earlier being we and give as really spot the that which you're a you that see have to us large happy full view in on, in I adding portfolio. you're team process, some likely that earlier these ramping development line of to. in engaged general, little development just outcome a actual commercial as

So would view be my long-term on a that basis.

Dan Brennan

on and you like? Could maybe Paul but guys you numbers of in strong any clinic, on, flow not, have think of I but it I how RFP your months, pipeline you the kind help of And earlier line what in any bookings you'd us looks Or the there the policy know, us, just what discussed X kind kind Alistair, have way of help the to about then is. yet? you sight bookings and that, mentioning this guys I that metrics year-over-year? is past, think Like in given mean the like that aren't looks give mentioned

Alistair Macdonald

see top more the when Well, XX as we I can it, we're we growth, in at those. mean looking penetrate obviously into

the leader execution-wise. So that the SMID still side. sector We're We're for market expanding. us still the expanding SMID on in probably is

think pipeline the record clinical I a now. earlier on more said And have on, we I side, As right have we capabilities.

a chances our chunk fancy we do. we So of closing of good that, like always

bar would which be. QX, for where of So be large right X.XXx, particularly together in were would cancellations us these in middle the and that to we at be want

off front we're take very out, at the and if of us. pipe that the happy we came cancellations, in happy where RFP with underlying, we're So we're quarter the you see pretty right

Jason Meggs

really of to compared last are Yes, in more add But I Dan, digits. point starting where time to double to last color was pipe, Xx we're what we're mean year. year is you mean, right, today the these or time, time SMID just, estimates, if up it this just as talking a these I seeing to little right? partnerships pipe up this where bit our that. is look And Xx the and shape at strength in

there's So the it to looks. revenue, to get through across you how it line, we got get that's sense a significant of feeding growth. give We to it and but got just

Operator

from comes Wolfe line Baxter the or from next Research. Our Stephen question comment of

Stephen Baxter

mine of Most asked. are

a ask can revenue you shortfall, quarter business. quick adjust time. this so with for on in something in margins ask I'll to I with like the one wanted the the It nature the decline was commercial numbers. So temporary about more sounds

QX margin big business. pretty in a that get the step-up typically you So in

by swing. make that's guidance how impacted So the kind we I sure think just want about to of

looking you quarter now I flatter think it a it looks for were in the and decline. will growth bit fourth like or maybe be little previously, a

fine-tune as trying to we we Or be about expect whether margin sort think should there's something QX business? normal So else just models? our a of should in considering progression that we if

Jason Meggs

Jason. Yes. Steve, it's

into guidance in by guidance do quarter pull show inherent quarter that but in million break for time When don't we look normalize forward the out that, gave, commercial our you when the segment, at in X was was we So that segment. X. from that X we year the a quarter that actuals. you $X last of XX%

you when guidance we and flat was normalize look were that, slightly margin actually up year-on-year. expected our in So And for expectation when at actually you we our what a from commercial the percentage. quarter, to

right, a margin that the normalize up to the XQ a challenges, bit, XX% And but margin performed where the quarter despite business back up percentage a from last into be from finished that the will we line business So see perspective. year, at three. normal we into back more XQ do certainly range. move When down you moving revenue

Stephen Baxter

one And last the Got of color just it. clarification. there. appreciate I kind then

today You business? are year the whether related Or trend on maybe about Just going wins. margins up the have similar capacity overall therefore, purely next company? about something of just trying side about guys it's there? think being be there provider whether consider you down growth to do potentially clinical the both the handle clinical as business being for to incremental guys and these you Or talking staffing ahead to talked Is adequate to of preferred commercial? in

Jason Meggs

start. I'll Well,

clarify down as year across relationships, we margin margin operating still working get we of the of like the through, segment thing XXXX. we still XX accretion that is relationships do these to leverage level pulling next margins company. basis expect We being XX anticipate So are nature. out would view in not But to grow of have through we that, while of the and and and business. get things I our growth a one are to We up points standing

been turn relationship that next standing out, and that before. round have commercial Europe. in the that's That that one -- tailwind. large year about of some up, a do we we side, a year, And and will On continue to to talked we've hope we that headwind as this a has little margin bit look into

at as the well. the X So as we just we're the commercial. that looking But not have in on and that have do clinical commercial phenomena we for given significant, it's X side

Operator

the to additional over management the queue questions in turn back time. I'd no to showing remarks. like any conference this I'm closing at for

Alistair Macdonald

Okay. you, Thank Howard.

for well pleased continued in driving growth very and year quarter, growth we're full So beyond. positioned our third continue XXXX we're and the with the to

opportunities strong RFP remains pipeline integrated outsourcing and Our customer robust, flow operations strategic our investments solutions. of our and driven interest and very in by

great you and today very investment a in gentlemen, for your and Health. be ladies Syneos interest attendance day for good. thank and So Have much, your and

Operator

today's has and for Ladies Thank call your conference participation. concluded. gentlemen, you

disconnect. now may You

Syneos Health (SYNH) 2 Nov 192019 Q3 Earnings call transcript